Exhibit 99.1 QXO Announces Launch of Term Loan Refinancing GREENWICH, Conn. — October 28, 2025 — QXO, Inc. ("QXO" or the "Company") (NYSE: QXO) today launched a refinancing of its Term Loan B. The refinancing is subject to market and other conditions, and no assurances are made that the Company will consummate the refinancing on the terms contemplated, or at all. In connection with the refinancing, the Company provided to potential lenders the following summarized preliminary financial information. The Comp ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☑ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended September 30, 2025 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File No. 0-15950 FIRST BUSEY CORPORATION (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (I.R.S. Em ...

EXHIBIT 99.1 NERDWALLET REPORTS THIRD QUARTER 2025 RESULTS Revenue of $215.1 million, Up 12% Year-Over-Year FINANCIAL HIGHLIGHTS SAN FRANCISCO, CA—November 6, 2025—NerdWallet, Inc. (Nasdaq: NRDS), which provides trustworthy financial guidance to consumers and small and mid-sized businesses (SMBs), today reported financial results for its third quarter ended September 30, 2025. "Our performance marketing and operational efficiency gains in the past few quarters have set us up for long-term growth and resulte ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 (212) 891-2880 (Registrant's telephone number, including area code) Portman Ridge Finance Corporation TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 814-00735 BCP Investment Corporation (Exact nam ...

Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update – Announced positive data from the ongoing Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer – • Announced positive data from the ongoing CRDF-004 Phase 2 randomized trial evaluating two doses of onvansertib in combination with standard of care ("SoC") for the treatment of first-line RAS-mutated metastatic colorectal cancer ("mCRC") o As of ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-36309 INOGEN, INC. Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________ FORM 10-Q ________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-41072 ________________________ IR ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________ FORM 10-Q _____________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39759 _______________________ ...

Cell Processing revenue of $25.4 million, up 33% over Q3 2024 GAAP gross margin of 62% and non-GAAP adjusted gross margin of 64% GAAP net income of $0.6 million and non-GAAP adjusted EBITDA of $7.8 million or 28% of revenue Raises 2025 full-year Cell Processing revenue guidance to $93.0 million - $94.0 million; Full-year total revenue guidance to $95.0 - $96.0 million, adjusted for the recent sale of its evo cold chain logistics subsidiary Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash ...

Exhibit 99.1 Natera Reports Third Quarter 2025 Financial Results AUSTIN, Texas, November 6, 2025 / Business Wire/ — Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the third quarter ended September 30, 2025. Recent Financial Highlights "Results in the third quarter were excellent, including our largest increase in quarterly clinical MRD units to date," said Steve Chapman, chief executive officer of Natera. "We continue to advance ...